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Abstract 
Gastrointestinal  stromal  tumors  (GISTs)  are  rare  abdominal  tumors  which  arise  from  the 
interstitial cells of Cajal in the gastrointestinal tract. Gastric GISTs are the most commonly 
seen  GIST  tumors  and  may  grow  to  a  very  large  size.  They  are  often  associated  with 
abdominal  pain,  anorexia  and  weight  loss.  Most  of  them  can  be  detected  by  CT.  These 
tumors have been found to harbor mutations in CD117 which causes constitutional activation 
of  the  tyrosine  kinase  signaling  pathway  and  is  considered  to  be  pathognomic.  Tyrosine 
kinase inhibitors such as imatinib have revolutionized the treatment of these tumors, which 
are otherwise resistant to conventional chemotherapy and radiotherapy. Although surgical 
resection  is  the  mainstay  of  treatment,  tyrosine  kinase  inhibitors  have  been  useful  in 
prolonging the recurrence-free survival of these patients. Resistance to imatinib has been 
reported in GISTs with specific mutations. We present a case of gastric GIST which grew to a 
very large size and was associated with abdominal pain and weight loss. It was successfully 
resected and the patient was commenced on imatinib therapy. 
Introduction 
Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors that may arise from 
any part of the gastrointestinal tract. GISTs have been shown to originate from the intersti-
tial cells of Cajal, which are located in the submucosal and myenteric plexus of the gastroin-
testinal tract [1–3]. GISTs are rare tumors and comprise less than 1% of all gastrointestinal 
tumors, and it is estimated that up to 6,000 new cases are diagnosed in the US every year [4, 
5]. This likely represents an underestimation as many smaller-sized GISTs may go undetect-
ed [6, 7]. They are rarely detected in children and present with metastasis in adults over the  
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age of 50 years [8]. An equal distribution in gender has been observed though there have 
been  reports  of  a  male  preponderance  [9].  GISTs  present  as  round  masses  with  clearly 
defined  borders  arising  from  the  submucosal  layer.  Based  on  their  histology,  they  are 
divided  into  eight  subtypes,  but  all  of  them  stain  for  the  stem  cell  factor  receptor 
(CD117/KIT) [10]. GISTs which do not express KIT may express alpha-type platelet-derived 
growth factor receptor (PDGFRA), protein kinase C theta (PKC-θ) and discovered on GIST-1 
(DOG-1)  [11–13].  Malignancies  such  as  melanoma,  mastocytoma,  Ewing’s  sarcoma,  lung 
small cell carcinoma, etc. may also express KIT, and their presence in the gastrointestinal 
tract likely represents metastases and they need to be distinguished from GISTS [14–16]. An 
autosomal dominant pattern of inheritance has been described in familial GIST  [17–19]. 
Mutations involving succinate dehydrogenase subunits B, C and D have been observed in the 
familial form of GIST [20]. GISTs have been observed in the small intestine of patients with 
neurofibromatosis type-1 [21, 22]. A separate inherited syndrome consisting of paragangli-
omas and GISTs has also been described [23]. 
Gastric GISTs are known to reach sizes exceeding 40 cm and have a better prognosis 
than intestinal GISTs of similar size and mitotic rate [10]. Extraintestinal GISTs (EGISTs) 
have been reported in the gall bladder, urinary bladder and rectovaginal septum [24–26]. 
EGISTs are considered to be metastases but paradoxically exhibit a better overall prognosis 
[27]. CT scans and endoscopic ultrasound are commonly used diagnostic modalities. 
Case Summary 
The patient is a 41-year-old male with a past medical history significant for type 1 diabe-
tes, gastroesophageal reflux disease and hypertension. He presented in our gastroenterology 
clinic with abdominal discomfort, distention and unintentional weight loss of 24 pounds 
over the past 2 months. The patient underwent a CT scan of the abdomen which revealed a 
20-cm epigastric mass with several areas of necrosis suggestive of hemangioma of the liver. 
The  patient  was  scheduled  to  be  seen  in  the  general  surgery  clinic,  but  his  symptoms 
worsened and he presented to our hospital with a fever of 102 F and worsening abdominal 
pain. A repeated CT scan of the abdomen revealed a large heterogeneous mass measuring 31 
× 10 × 26 cm, predominantly solid and containing small cystic areas in the right abdomen 
and pelvis. The patient was admitted to the medical service where he became hypotensive 
and anemic with a significant hematocrit drop. The patient was hemodynamically stabilized 
and  underwent  an  arterial  embolization  of  the  gastroduodenal  artery  to  control  the 
hemorrhage. Thereafter,  the patient underwent  resection of the tumor en bloc  with the 
stomach, gastrectomy, Billroth II reconstruction and wedge biopsy of segment six of the 
liver. The patient tolerated the procedure well, with no significant post-operative complica-
tions. On gross examination, the tumor measured 34 cm in its greatest dimension,  with 
notable hemorrhage and necrosis (fig. 1). Microscopic examination and immunohistochemi-
cal staining confirmed the tumor to be a GIST with tumor cells staining positive for CD117 
(fig. 2a, b). Segment 6 of the liver was reported as metastatic GIST. The patient was started 
on chemotherapy with imatinib. 
Discussion 
The most common site of occurrence for GISTs is the stomach (60%) followed by the 
small intestine (30%) [28]. It is difficult to distinguish extraintestinal GISTs from metastases.  
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The  mainstay  of  management  of  GISTs  is  surgical  resection  when  possible.  Regional 
lymphadenectomy  is  not  advocated  as  GISTs  have  not  been  observed  to  metastasize  to 
lymph nodes [29, 30]. However, there is a very high risk of recurrence if there is intraperito-
neal rupture or spillage during surgery [31]. The 5-year overall survival in patients with 
complete resection has been estimated to be superior compared to that of patients with 
incomplete resection (42 vs. 95%) [32]. Tyrosine kinase inhibitors such as imatinib have 
been successfully used to treat GISTs [33]. KIT mutations cause constitutive activation of 
tyrosine kinase and the most common mutations are duplications in the 3 region of exon 11 
of the KIT gene. Mutations involving codons 557–558 and point deletions carry a worse 
prognosis [34]. Imatinib resistance has been noted in patients with PDGFRA mutations in the 
absence  of  KIT  mutations  [35].  Chromosomal  losses  at  1p,  14q  (gastric  GISTs),  15q 
(intestinal GISTs) and 22q have been observed, and the type of mutations have been noted to 
correlate with the response to imatinib [36, 37]. Mitotic rate, tumor size and location have 
been utilized for predicting the risk of progression in completely resected primary GISTs [38, 
39]. 
Considering that GISTs may reach large sizes and therefore making surgical resection 
risky, neoadjuvant therapy with tyrosine kinase inhibitors has been utilized to reduce their 
size. This strategy has been used to reduce surgical morbidity and improve the operability of 
these tumors [40, 41]. However, the mutational status (KIT vs. PDGFRA) of the tumor largely 
determines the effect of preoperative tyrosine kinase inhibitor therapy and monitoring of 
response by PET scan is advised. A duration of 4–6 months of neoadjuvant therapy with 
continuous monitoring has been recommended [42, 43]. Up to 66% of patients with high-
risk GISTs who have undergone resection experience recurrence [44]. The American College 
of  Surgeons  Oncology  Group  (ACOSOG)  Z9000  clinical  trial  showed  that  patients  with 
PDGFRA mutations had the best outcomes with 90% recurrence-free survival at 3 years. The 
ACOSOG Z9001 trial involved adjuvant therapy with 400 mg of imatinib and resulted in 98% 
recurrence-free survival [45]. The dosing and the type of tyrosine kinase inhibitors that are 
optimal for the patient’s treatment depend on the type of mutation [46–48]. Abdominal CT, 
MRI and PET scans have been used for follow-up and for monitoring the progression of the 
disease [49]. The follow-up frequency has ranged from months to years and depends on the 
risk profile of the initial disease [50]. 
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Fig. 1. Excised tumor with a part of the stomach. The gastric mucosa can be seen in the lower part of the 
specimen. 
 
 
 
Fig. 2. a Hematoxylin and eosin staining of the tumor shows a mildly eosinophilic cytoplasm. b CD117 
staining with a membranous distribution is shown. 
 